Total Valuation
Filana Therapeutics has a market cap or net worth of €35.08M. The enterprise value is -€25.19M.
Market Cap€35.08M
Enterprise Value-€25.19M
Share Statistics
Filana Therapeutics has 48,307,896 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding48,307,896
Owned by Insiders2.79%
Owned by Institutions1.03%
Financial Efficiency
Filana Therapeutics’s return on equity (ROE) is -1.22 and return on invested capital (ROIC) is -128.00%.
Return on Equity (ROE)-1.22
Return on Assets (ROA)-0.77
Return on Invested Capital (ROIC)-128.00%
Return on Capital Employed (ROCE)-1.28
Revenue Per Employee0.00
Profits Per Employee-4.79M
Employee Count19
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Filana Therapeutics is ―. Filana Therapeutics’s PEG ratio is -0.00428.
PE Ratio―
PS Ratio0.00
PB Ratio1.33
Price to FCF-3.02
Price to Operating Cash Flow-1.99
PEG Ratio-0.00428
Income Statement
In the last 12 months, Filana Therapeutics had revenue of 0.00 and earned -90.97M in profits. Earnings per share was -1.88.
Revenue0.00
Gross Profit-936.00K
Operating Income-95.39M
Pretax Income-90.97M
Net Income-90.97M
EBITDA-90.04M
Earnings Per Share (EPS)-1.88
Cash Flow
In the last 12 months, operating cash flow was -19.82M and capital expenditures -602.00K, giving a free cash flow of -20.43M billion.
Operating Cash Flow-19.82M
Free Cash Flow-20.43M
Free Cash Flow per Share-0.42
Dividends & Yields
Filana Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.53
52-Week Price Change-79.94%
50-Day Moving Average0.75
200-Day Moving Average1.24
Relative Strength Index (RSI)47.94
Average Volume (3m)67.00
Important Dates
Filana Therapeutics upcoming earnings date is Nov 11, 2026, TBA (Confirmed).
Last Earnings DateAug 5, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Filana Therapeutics as a current ratio of 2.23, with Debt / Equity ratio of 0.00%
Current Ratio2.23
Quick Ratio2.23
Debt to Market Cap0.00
Net Debt to EBITDA1.06
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Filana Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Filana Therapeutics EV to EBITDA ratio is -0.04, with an EV/FCF ratio of -0.11.
EV to Sales0.00
EV to EBITDA-0.04
EV to Free Cash Flow-0.11
EV to Operating Cash Flow-0.11
Balance Sheet
Filana Therapeutics has €82.68M in cash and marketable securities with €0.00 in debt, giving a net cash position of €82.68M billion.
Cash & Marketable Securities€82.68M
Total Debt€0.00
Net Cash€82.68M
Net Cash Per Share€1.71
Tangible Book Value Per Share€1.54
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Filana Therapeutics is €5.78, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€5.78
Price Target Upside622.91% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast67.88%